当前位置: X-MOL 学术Org. Process Res. Dev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Development of the Synthetic Route to PF-06878031 Part 2: Amide Reduction Route
Organic Process Research & Development ( IF 3.4 ) Pub Date : 2024-04-19 , DOI: 10.1021/acs.oprd.4c00054
Maria S. Brown 1 , Julia Buck 2 , Douglas J. Critcher 2 , Andrew M. Derrick 2 , Harriet Fenton 2 , Steven J. Fussell 2 , Adam E. S. Gymer 2 , Michael Hawksworth 2 , Heather Ingram 2 , Rebecca A. Johnson 2 , Rajesh Kumar 1 , Daniel A. Laity 2 , Russell D. Lewis 1 , Jinu S. Mathew 2 , Laura McGivern 3 , Ian B. Moses 2 , Andrew T. Palaia 1 , Miheal J. Patel 2 , James Rellegue 2 , Emily K. Rose 2 , Adam Scott 2 , Jeremy Steflik 1 , Steven J. R. Twiddle 2
Affiliation  

The target compound PF-06878031 is a key structural fragment of a range of oral late-stage glucagon-like peptide-1 receptor agonists (GLP-1-RA) under development in our laboratories for the indications of type 2 diabetes mellitus (T2DM) and weight loss. This article describes the identification of an amide reduction route, and development of a process, capable of delivering multikilo quantities of PF-06878031. The process development afforded improved safety, higher yield, a reduced step count, and a significant cost reduction. The new process has been scaled up at multiple facilities to generate >1.5MT of high-purity PF-06878031.

中文翻译:

PF-06878031 合成路线的开发第 2 部分:酰胺还原路线

目标化合物PF-06878031是我们实验室正在开发的一系列口服晚期胰高血糖素样肽-1 受体激动剂 (GLP-1-RA) 的关键结构片段,用于治疗 2 型糖尿病 (T2DM)和减肥。本文介绍了酰胺还原路线的确定以及能够提供数千份PF-06878031的工艺的开发。该工艺开发提高了安全性、提高了产量、减少了步骤数并显着降低了成本。新工艺已在多个工厂扩大规模,可生成 >1.5MT 的高纯度PF-06878031
更新日期:2024-04-19
down
wechat
bug